55687-02-0

Basic information

• Product Name: 6-bromo-2-chloroquinoxaline
• Synonyms: 6-bromo-2-chloroquinoxaline;Quinoxaline, 6-bromo-2-chloro-
• CAS NO: 55687-02-0
• Molecular Formula: C₈H₄BrClN₂
• Molecular Weight: 243.49
• Product Categories: CHIRAL CHEMICALS
• Mol File: 55687-02-0.mol
• Article Data: 10

Chemical Properties

• Melting Point: 150-152.5 °C
• Boiling Point: 312.5 °C at 760 mmHg
• Flash Point: 142.8 °C
• Appearance: /
• Density: 1.762 g/cm³
• Vapor Pressure: 0.000966mmHg at 25°C
• Refractive Index: 1.691
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -2.46±0.30(Predicted)
• CAS DataBase Reference: 6-bromo-2-chloroquinoxaline(CAS DataBase Reference)
• NIST Chemistry Reference: 6-bromo-2-chloroquinoxaline(55687-02-0)
• EPA Substance Registry System: 6-bromo-2-chloroquinoxaline(55687-02-0)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 55687-02-0(Hazardous Substances Data)

Usage

General Description

6-bromo-2-chloroquinoxaline is a chemical compound with the molecular formula C8H5BrClN2. It is a heterocyclic organic compound containing a quinoxaline ring with bromine and chlorine substituents at the 6 and 2 positions, respectively. 6-bromo-2-chloroquinoxaline is commonly used in organic synthesis as a versatile building block for the preparation of various pharmaceuticals and agrochemicals. It is also known for its antimicrobial and antiviral properties and has been studied for its potential in drug development. 6-bromo-2-chloroquinoxaline is available as a commercial chemical and is used in research and development laboratories as well as in the pharmaceutical and agrochemical industries.

InChI:InChI=1/C8H4BrClN2/c9-5-1-2-6-7(3-5)11-4-8(10)12-6/h1-4H

Upstream product

• 55687-34-8 6-bromoquinoxalin-2(1H)-one 
• 1196-57-2 quinoxalin-2⁽¹⁾-one 
• 1196-57-2 2-hydroxyquinoxaline 
• 321-23-3 4-bromo-2-fluoronitrobenzene 
• 1486183-97-4 ethyl 2-(5-brom9-2-nitro-anilino)acetate 
• 854584-01-3 6-bromo-3,4-dihydroquinoxalin-2(1H)-one 

Downstream Products

• 1071605-38-3 6-bromo-quinoxalin-2-ylamine 
• 112080-07-6 6-Bromo-2-fluoro-quinoxaline 
• 21335-55-7 n-pentenyl alcohol 
• 1257090-13-3 (6-bromo-quinoxalin-2-yl)[(R)-1-(3-methoxy-phenyl)ethyl]amine 
• 1257090-01-9 (6-bromoquinoxalin-2-yl)-((R)-1-phenylethyl)amine 
• 1257090-15-5 (6-bromoquinoxalin-2-yl)-[(R)-1-(3-chlorophenyl)ethyl]amine 
• 1257090-09-7 (6-bromo-quinoxalin-2-yl){(R)-1-[3-(4-methyl-piperazin-1-yl)phenyl]ethyl}amine 
• 1261071-89-9 tert-butyl (2S)-2-(5-{4-[6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinoxalin-2-yl]phenyl}-1H-imidazol-2-yl)pyrrolidine-1-carboxylate 
• 1261071-90-2 tert-butyl (2S)-2-(5-[2-(4-{2-[(2S)-1-(tert-butoxycarbonyl)pyrrolidin-2-yl]-1H-imidazol-5-yl}phenyl)quinoxalin-6-yl]-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-imidazol-2-yl)pyrrolidine-1-carboxylate 
• 1261071-93-5 tert-butyl (2S)-2-(5-[6-(4-{2-[(2S)-1-(tert-butoxycarbonyl)pyrrolidin-2-yl]-1H-imidazol-5-yl}phenyl)quinoxalin-2-yl]-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-imidazol-2-yl)pyrrolidine-1-carboxylate 
• 1228633-28-0 6-{2-[(2S)-pyrrolidin-2-yl]-1H-imidazol-5-yl}-2-(4-{2-[(2S)-pyrrolidin-2-yl]-1H-imidazol-5-yl}phenyl)quinoxaline 
• 1228552-66-6 methyl {(2S)-1-[(2S)-2-{5-[4-(6-{2-[(2S)-1-{(2S)-2-[(methoxycarbonyl)amino]-3-methyl-butanoyl}pyrrolidin-2-yl]-1H-imidazol-5-yl}quinoxalin-2-yl)phenyl]-1H-imidazol-2-yl}pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl}carbamate 
• 1261070-29-4 methyl {(2S)-1-[(2S)-2-{5-[4-(2-{2-[(2S)-1-{(2S)-2-[(methoxycarbonyl)amino]-3-methyl-butanoyl}pyrrolidin-2-yl]-1H-imidazol-5-yl}quinoxalin-6-yl)phenyl]-1H-imidazol-2-yl}pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl}carbamate 
• 1261071-94-6 2-{2-[(2S)-pyrrolidin-2-yl]-1H-imidazol-5-yl}-6-(4-{2-[(2S)-pyrrolidin-2-yl]-1H-imidazol-5-yl}phenyl)quinoxaline 

Relevant articles and documents

HETEROCYCLIC COMPOUNDS

The present invention provides a compound represented by the formula (I) wherein each symbol is as defined in the specification, or a salt thereof has an BET family protein inhibitory action, and is useful as an agent for the prophylaxis or treatment of autoimmune diseases and/or inflammatory diseases (e.g., rheumatoid arthritis, multiple sclerosis, idiopathic pulmonary fibrosis, psoriasis, atopic dermatitis, inflammatory bowel disease, Sjogren's syndrome, Behcet's disease, systemic lupus erythematosus etc.), cancer and the like.

The discovery of potent nonstructural protein 5A (NS5A) inhibitors with a unique resistance profile - Part 1

Nonstructural protein 5A (NS5A) represents a novel target for the treatment of hepatitis C virus (HCV). Daclatasvir, recently reported by Bristol-Myers-Squibb, is a potent NS5A inhibitor currently under investigation in phase 3 clinical trials. While the performance of daclatasvir has been impressive, the emergence of resistance could prove problematic and as such, improved analogues are being sought. By varying the biphenyl-imidazole unit of daclatasvir, novel inhibitors of HCV NS5A were identified with an improved resistance profile against mutant strains of the virus while retaining the picomolar potency of daclatasvir. One compound in particular, methyl ((S)-1-((S)-2-(4-(4-(6-(2-((S)-1-((methoxycarbonyl)-L-valyl)pyrrolidin-2-yl) -1H-imidazol-5-yl)quinoxalin-2-yl)phenyl)-1H-imidazol-2-yl)pyrrolidin-1-yl) -3-methyl-1-oxobutan-2-yl)carbamate (17), exhibited very promising activity and showed good absorption and a long predicted human pharmacokinetic half-life. This compound represents a promising lead that warrants further evaluation. Resisting resistance: An investigation into the anti-hepatitis C virus (HCV) replicon activity of a series of biaryl-linked pyrrolidine NS5A inhibitors explored a diverse range of core structure modifications as key determinants of antiviral activity and susceptibility to common resistance mutations. Further evaluation of several core structure designs identified a compound with excellent pharmacokinetics, suitable for once daily dosing.

HEPATITIS C VIRUS INHIBITORS

The present invention relates to compounds of the formula (I) and pharmaceutically acceptable salts thereof, to compositions containing such compounds and to the use of such compounds as inhibitors of HCV replication.